We would love to hear your thoughts about our site and services, please take our survey here.
Thanks 91Divoc. Here is an exert from that article:
"However, the rating is modest for a company that is aiming to become a £100mn revenue business by 2028, buoyed by organic growth of 8-10 per cent per year and the contribution from synergistic bolt-on acquisitions.
Offering decent upside to Cavendish’s and Investec’s upgraded target prices of 40p and 41p (from 38p), and the more conservative valuations of Liberum (34.5p) and Stifel (35p), hVIVO’s shares continue to rate a buy."
Hi All long term holders. I have been with this from the Open Orphan Covid highs down to the post Covid hVIVO lows.
I have significant exposure (like many probably too much exposure). I am relieved to be back up, knocking on the door of 30p again.
I thought I would be more inclined to sell as the share price recovered, but with the new facility coming online, a very healthy order book and long term visibility, JP Morgan taking a sizable stake, another dividend on its way and increased diversity in the challenge studies offered, I find myself happy to continue holding and see how this plays out.
The share price has been much less volatile with positive sentiment and increased institutional ownership giving it more of a platform. Also the business itself is solid with positive cash flow and money in the bank.
Some talk of a sale, but I think regardless of what happens, things are looking really good. If the upcoming results underpin all of this, which I think they will, my instinct is that we will move up to the low 30s in the medium term. If news unknown news, such as M&A, or contracts that show the size of the company's bigger contract abilities, a few more TR1s, or something like a malaria trial I think these could move the share price into new territory. GLA.
Sounds like you know nothing about the company Colin60.
Sounds like you nothing about the company Colin60.
Seems that the V*x markets website needs a login. Same chat also on YouTube.
Hvivo segment from about 50 mins in:
https://youtu.be/aam5NAflRZs
Moniman. I didn’t see Dennis the Menace in the Times.
Thanks Zinc, yes it is all spreading awareness of the company.
Was down at my Dad’s and opened his copy of Moneyweek from 10th Feb. Each month they mention one share tip from each of a range of publications like the Mail, Telegraph, Interactive Investor etc. I was happy to see them reference the recent Times article:
"Hvivo
The Sunday Times
This Aim-listed tester of infectious disease treatments works with the likes of Pfizer, GSK, Janssen and Merck on early stage “human challenge trials” to determine whether candidate treatments for “flu, malaria, asthma and Covid” have what it takes to proceed to larger studies. There is always the risk of a trial going disastrously wrong, but with 60 human studies behind it the firm has plenty of experience in managing the dangers. With memories of the pandemic promoting greater interest in respiratory health, this is “a well-run, defensive stock with plenty of growth potential”. 16p"
Yes, extrader, I noticed that too!
Also noticed this one this morning. Apologies if already posted before. Just a mention, but all increases awareness right...
https://www.fool.co.uk/2023/02/06/best-british-small-cap-stocks-to-buy-for-february/
f o o l
Interesting that Hvivo's Director of Business Development for Europe and Asia, Egle Pavyde, was the one being interviewed.
Just watching one of today’s videos. Mo just said, "More news will follow in April/May this year."
So I am assuming he is referring to YE. It would make sense as I seem to remember them saying that they would try to be earlier this year.
Nice video. For those who don’t know: v o x m a r k e t s
Profitbagger, yes we can agree from different directions! We both want this share to prosper.
It is so good to see some sanity and excitement returning to the share.
Profitbagger - "Charlatan O'Spiel" - really?? He is the one who said a year or two ago that Hvivo should pay dividends. Now it seems it will. He was the one who has spun out Poolbeg, a way more comprehensive company than anyone ever expected. He is the one who has laid the groundwork for where the company is today. He is still the chairman and will be having a hand in all this that is going on now. He is the one who will probably come up with another IPO this year.
It is so easy to bash him. But big companies are down 50% plus right now. And it seems like it is coming to pass that indeed the Hvivo share price is undervalued and is undergoing a rerate. Yes, he made some optimistic projections, but we all have a duty to do our own due diligence. And no one can predict the market short term.
I believe, and it is has been implied in presentations, that Cathal and Mo are trying to be more professional in their reporting and media engagements in order to bring on more institutional investors. I think this is also why the spin outs are mostly out of sight now. My personal view is that when they have more solid news on the spin outs they will be announced and swiftly dispatched because of the institutional investors.
But the downside of all this is that there is less hype about. And people have to take it on faith that the spin offs will be delivered and that profits will come. I believe it will happen this way, but others see it differently. And that is just a difference of opinion.
It is a tough hold right now, but so are many, many shares, but I would say is a good buy as part of a balanced portfolio. I continue to hold. A couple more contract wins will solidify the share price again in the 10-15p range I would say. And any big contracts (£14 million plus) with some of the expanded services they are now offering included would demonstrate new avenues opening up, and could increase confidence and the price too.
My personal view is that stock is in that awkward stage between being valued on sales and valued on profit. The quicker Mo can bring some recognisable profit, and increase the cash pile, the better. I think spins off are not even recognised at all in the current price as most are not considering now.
I would love to see them buy some shares back too. That could move the needle too.
This is all my personal opinion. Not advice.
Like others have said the business is healthy from many angles. It has cash, it is making intelligent decisions by expanding its offerings and has forward sight on sales.
It’s market cap now is round about £60 million today. It probably has £20 million in cash. And it will remain somewhat unaffected by a recession.
By definition a stock stops falling when the bears stop selling. Sentiment and bad headlines in the media about the markets in general can cause panic. But at approximately 1x forward sales this stock will have a bottom hopefully any time soon. Lots of their customers are paying in dollars too, which actually is a good thing as it makes things cheaper from a dollar point of view.
I too was disappointed with a target of £55 million next year. I would imagine they will do more than this, so why not at least say £60m. We are now in a genuine under promise and over deliver leadership following what could be described as an over promise environment previously.
Personally, I believe they really want to deliver the spins outs as soon as possible. For this to happen I believe POLB needs to be above the IPO price of 10p. This could feasibly happen by year end if the POLB1 challenge studies come through well. And they of course need this crazy global atmosphere to be more accommodating for DIM to IPO. Let’s hope that comes along early 2023.
From listening to Mo talk, I think he is really focused on delivering profits from the turnover they have. This will really help the share price too. As a CRO Open Orphan, soon to be Hvivo, is below what is considered a normal valuation.
Ash. I find your views simplistic. You call him ‘Mr Friel" that seems like respect, but you are then so disrespectful. You say you have a list as if this is reason enough. Any investor must value a company themselves. Not just take one person’s word, CEO or not. We must all take responsibility for our buys and our research. Cathal Friel did not make you buy these shares.
Yes CF talked about doubling the share price very 6 months I think it was. Yes, he probably shouldn’t have said that. But you need to evaluate that. Yes, the time lines were too ambitious. But I now sit on shares of a really exciting new company. There’s new facilities now. New challenge studies. It slower than I’d like. But investing is a endeavour of years.
Personally I think the share price would have taken a similar trajectory regardless of the over promising. But that is just my opinion. But even so, nothing is guaranteed.
Now everyone must evaluate the share price on their own terms. You seem to think there is 45 p of value here for a sale. So wait for the sale or don’t. You are basically applying a downward pressure on the share price with your posts and attacks. I’m conscious I’m might be just stoking the fire by replying. I wonder if you might just be short on ORPH, and attempting to deramp.
I haven't posted for a long time. I became a bit disillusioned with the short term negative posting. Every famous investor, and I mean "investor" talks about how you have to be able to ride out dips in share price to outperform the market. Every high value company, like Amazon and Apple, have had massive dips percentagewise. And all the research says that you need to be in the market, ready for the days when the share price moves.
We have been in this area for a while with Orph, and I feel the sellers are getting exhausted. Ask yourself if you believe in this company. Calling for heads to roll doesn't help anyone. Cathal Friel has spun out, what looks to be, a superb company in Poolbeg. And like he said he would, he appointed a very solid CEO.
I realise biotech is suppressed, as are many areas. The growth stocks in USA are devastated. I am excited to see what is next. There are spin outs. And Orph's "likely" business, not already RNSd, was £75 million if I remember correctly. Disease in Motion could be another great business.
I'm not saying everyone should blindly hold their shares. But like the saying goes, if you liked Orph at 30p, you should love it at 15p, as long as you still have capital to buy more. I am personally cannot allow myself to buy any more Orph, as it is a large percentage already. But I would do. Good luck to all. If I zoom out, I suspect in a year or two I will be extremely happy.
No, wasn't in your dreams. But in recent interviews he has in a round about way said they are going to keep the cash for now and put their efforts into DIM.